Clinical trials: B-Cell Non-Hodgkin Lymphoma-Refractory
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Myeloproliferative Disorders, Leukemia
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782145
- Testing
- educational intervention, informational intervention, internet-based intervention
- Where
- 6 sites in United States
- Volunteers
- 198 people
- Sponsor
- Tufts Medical Center
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute…
- Conditions
- Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia, T-cell Non-Hodgkin's Lymphoma
- Trial name
- BCX1777-108 (NCT00742495)
- Testing
- Forodesine
- Where
- 6 sites in Austria, Czechia and 4 more
- Volunteers
- 2 people
- Sponsor
- Mundipharma Research Limited
ALL, Burkitt's Lymphoma
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
Assess the safety, tolerability and efficacy of rapamycin in combination with HiVAC in relapsed and refractory patients with aggressive lymphoid malignancies.
- Conditions
- ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
- Trial name
- UPCC 25406 (NCT00776373)
- Testing
- Rapamycin, High dose etoposide and cytarabine (HiVAC)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
B Cell Lymphoma
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07093073
- Testing
- ssCART-19
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Lymphoma, B-cell Lymphomas
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell…
- Conditions
- Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- GLORY (NCT07711483)
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Non-Hodgkin
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.
- Trial name
- TRANSCEND FL (NCT04245839)
- Testing
- Fludarabine, Cyclophosphamide, JCAR017
- Where
- 49 sites in United States, Austria and 8 more
- Volunteers
- 276 people
- Sponsor
- Celgene
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04796857
- Testing
- PD-1 Antibody, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huiqiang Huang
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Leukemia, B-Cell
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic…
- Trial name
- NCT03599375
- Testing
- CD19-targeted CART cells
- Volunteers
- 20 people
- Sponsor
- jiuwei cui
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma.
- Trial name
- NCT00655837
- Testing
- SGN-40, rituximab, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
This phase I trial studies the highest possible dose of memory enriched T cells that can be given following standard stem cell transplant before unmanageable side effects are seen in patients with B-cell non-Hodgkin lymphoma that…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT02051257
- Testing
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B-cell Lymphoma (DLBCL)
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase I/II, open-label, multicenter, prospective study.
- Trial name
- NCT02957019
- Testing
- L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Philogen S.p.A.
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Background: B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the…
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia
- Trial name
- NCT03448393
- Testing
- CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the pharmacokinetics, safety, tolerability, and efficacy of glofitamab as a single agent following a fixed single dose of obinutuzumab in Chinese patients with relapsed or refractory (R/R) diffuse large…
- Trial name
- NCT04657302
- Testing
- Obinutuzumab, Glofitamab, Tocilizumab
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+…
- Trial name
- NCT03189836
- Testing
- ACTR707, rituximab
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cogent Biosciences, Inc.
Refractory B-Cell Lymphoma
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
- Trial name
- NCT03692767
- Testing
- Anti-CD22 CAR NK Cells
- Volunteers
- 9 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.